Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Why TB patients are treated with drugs
- Natural history and control of TB
- Streptomycin in TB treatment
- Combination therapy of TB
- DOTS strategy (1)
- DOTS strategy (2)
- Reduction in TB death rate
- How drug resistance arises
- Resistance genes
- Mechanism of resistance
- Evolution of resistance by natural selection
- Resistance causes treatment failure
- Initial resistance assists resistance to other drugs
- Risk of acquiring resistance after treatment failure
- Duration and regimen effect on MDR-TB cure rates
- Rifampin-resistant mutants of TB (1)
- Rifampin-resistant mutants of TB (2)
- Isoniazid resistant TB and MDR-TB: fitness
- Geographical distribution of drug resistant TB
- Treatment success reaches 85 percent target
- Reasons for treatment failure under DOTS
- Retreatment proportion: China vs. India
- Cure rates are lower for MDR-TB patients
- 510,000 people developed MDR-TB in 2007
- MDR-TB among previously treated TB patients
- Countries reporting at least one XDR-TB case
- TB drug resistance and HIV
- XDR-TB outbreak in SA and HIV (1)
- XDR-TB outbreak in SA and HIV (2)
- Drug resistant TB is linked to HIV coinfection
- Reversing the spread of drug resistant TB
- TB rates in Europe and Africa
- Benign epidemic
- Severe epidemic
- TB strain prevalence: the USA
- TB strain prevalence: Hong Kong
- TB strain prevalence: Estonia
- TB strain prevalence: Russia
- Reproduction numbers world wide
- Reversing the spread of MDR-TB
- Spread of Beijing TB strains in Cape Town
- Summary
- References
Topics Covered
- Natural history and epidemiology of TB
- Discovery of antibiotics
- Drug combinations as used in TB control programmes worldwide
- How drug resistance arises
- Geographical distribution of drug-resistant TB
- TB drug resistance and HIV/AIDS
- Reversing the spread of drug-resistant TB
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Dye, C. (2015, August 6). Drug resistant tuberculosis: biology, epidemiology and control [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/IFPP1275.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Christopher Dye has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Drug resistant tuberculosis: biology, epidemiology and control
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Chris Dye and I'm the Director of Health Information for AIDS, TB,
Malaria, and other tropical diseases at the World Health Organization in Geneva.
Tuberculosis is still responsible for
more deaths each year than any other pathogen except HIV,
and drug-resistance is one of the most pressing problems in TB control today.
In 2008, WHO recorded more cases of drug-resistant TB than ever before.
Multidrug-resistant TB, which is resistant to the two main first line drugs,
has been found in every country that's looked for it,
and by March 2009, extensively drug-resistant TB,
which is resistant to both first and second line drugs,
have been found in more than fifty countries around the world.
Scientists are now talking more frequently about the end of the antibiotic era.
So are we on the point of losing control of TB all together,
hope it would returned in the 21st century to the days
when TB killed half of all patients that contracted the disease?
1:04
I'm going to divide this discussion of antibiotic resistance into five parts.
In the first part, I want to explain why we have to treat TB with drugs at all.
I don't mean to suggest that people unlucky enough
to develop TB should go without treatment.
Rather, the question is,
why do we have to wait for people to get TB?
Why can't we prevent the disease in the first place?
This is important background to this story because,
if we use drugs less frequently,
then resistance to these drugs would emerge more slowly.
We would, in effect,
prolong the therapeutic life of our best antibiotics.
To see how and why we use TB drugs today,